Benevich Eric's Form 4/A amendment
AmendedNeurocrine Biosciences IncNBIX · filed Jan 16, 2026
- Accession no.
- 0001643653-26-000005
- Filed
- Jan 16, 2026
- Trade date
- Nov 28, 2025
- Filing delay
- 49 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Dec 2, 2025
This filing lists 1 non-derivative transaction and 1 derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $905.9K. It was filed 49 days after the trade.
This amendment restates part of 0001643653-25-000007 (filed Dec 2, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Benevich EricCIK 0001643653 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Stock | MOption exerciseAcquired | +12,830 | $35.99 | +$461,751.7 | 57,723 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Stock | MOption exerciseDisposed | −12,830 | $0.00 | $0 | 0 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001643653-25-000007 (filed Dec 2, 2025).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Stock | SSaleDisposed | −5,970 | $151.74F3 | −$905,887.8 | 44,893 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F3
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.70 to $153.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options.
- F2
Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F3
This line is included solely to report the Reporting Persons corrected beneficial ownership of Common Stock in Column 5 following the November 28, 2025 transactions previously reported in the Form 4 filed on December 2, 2025.
- F4
The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.